Dáil Éireann Debate, Tuesday - 2 February 2016
420. Deputy Billy Kelleher asked the Minister for Health the status of the provision of Fampyra and the restrictions that have been placed on covering the cost of the medication by the Health Service Executive; and if he will make a statement on the matter. [4592/16]
Amharc ar fhreagraFampridine (brand name Fampyra®) has been reimbursed under the Long Term Illness Scheme on a conditional, responder-only basis since 1 October 2015.
The HSE has provided all Neurology Centres with details of the protocol which must be satisfied to enable a patient to qualify for reimbursement.
Reimbursement will be extended where a demonstration of clinical response (based on objective criteria agreed with clinical experts) is recorded and where that clinical response is shown to persist, based on objective measurement at six-monthly intervals. The HSE extends reimbursement in all cases where the criteria meet the requirements of reimbursement protocol.
